Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Learn more about:
Related Clinical Trial
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule Optimising Molecular Radionuclide Therapy Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer Function Integrity of Neck Anatomy in Thyroid Surgery An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Evaluation of a New CZT System Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain A Study Into the Effect of Seprafilm in Open Total Thyroidectomy Lenvatinib and Pembrolizumab in DTC Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Influence of Thyroid Hormones on the Woundhealing Process ctDNA in Patients With Thyroid Nodules Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine Trial of LBH589 in Metastatic Thyroid Cancer Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma Thyroid Cancer and Sunitinib Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients Lipid Metabolic Status in Thyroid Carcinoma

Brief Title

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Official Title

Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers

Brief Summary

      This phase II trial studies how well iodine I-131 works with or without selumetinib in
      treating patients with thyroid cancer that has returned (recurrent) or has spread from where
      it started to other places in the body (metastatic). Many thyroid cancers absorb iodine. Due
      to this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer
      as part of standard practice. It is thought that the more thyroid tumors are able to absorb
      radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors
      to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still
      absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or
      without selumetinib in treating thyroid cancer.

Detailed Description


      I. To determine the response rate at 6 months following treatment with 131I (iodine I-131) in
      combination with placebo or selumetinib for radioactive iodine-avid (RAIA) recurrent and/or
      metastatic thyroid cancer.


      I. To determine the best overall response following treatment with 131I in combination with
      placebo or selumetinib for RAIA recurrent and/or metastatic thyroid cancer.

      II. To compare the progression-free survival of patients with RAIA recurrent and/or
      metastatic thyroid cancer treated with 131I in combination with placebo or selumetinib.

      III. To compare serum thyroglobulin changes for patients with RAIA recurrent and/or
      metastatic thyroid cancer treated with 131I in combination with placebo or selumetinib.

      IV. To evaluate the safety and tolerability of 131I in combination with placebo or
      selumetinib for patients with RAI-avid recurrent and/or metastatic thyroid cancer.


      I. To explore the genomic and transcriptomic landscape of RAIA tumors for signatures that
      correlate to therapeutic benefit achieved with 131I in combination with placebo or

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive selumetinib orally (PO) twice daily (BID) starting on week 1, day 1
      and continuing through 2 days after iodine I-131 therapy has been administered. Approximately
      3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.

      ARM II: Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2
      days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning
      treatment with placebo, patients receive iodine I-131 PO.

      After completion of study treatment, patients are followed up at 1 and 3 months, every 3
      months for 12 months, and then every 6 months for 2 years.

Study Phase

Phase 2

Study Type


Primary Outcome

Response at 6 Months

Secondary Outcome

 Best Overall Response


Metastatic Thyroid Gland Carcinoma


Iodine I-131

Study Arms / Comparison Groups

 Arm I (selumetinib, iodine I-131)
Description:  Patients receive selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

May 4, 2015

Completion Date

December 31, 2022

Primary Completion Date

July 17, 2020

Eligibility Criteria

        Inclusion Criteria:

          -  Diagnosis of recurrent and/or metastatic thyroid cancer

          -  Histological or cytological confirmation of thyroid carcinoma of follicular origin
             (including papillary, follicular, or poorly differentiated subtypes and their
             respective variants); NOTE: medullary and anaplastic thyroid cancers are excluded;
             Hurthle cell carcinomas are excluded (defined as having an invasive tumor composed of
             > 75% oncocytic [Hurthle] cells lacking the nuclear features of papillary carcinoma,
             tumor necrosis, and marked mitotic activity); patients with oncocytic (Hurthle cell)
             variants of papillary thyroid carcinoma (defined as a tumor composed of a majority of
             oncocytic [Hurthle] cells having the nuclear features of papillary carcinoma) are
             eligible to participate

          -  RAI-avid lesion on a radioiodine scan (a diagnostic, post-therapy, or post-ablation
             scans) performed =< 24 months prior to registration, which suggests that therapy with
             131I is justifiable in the judgment of the investigator

          -  Clinically or radiographically evident structural disease; patients with measurable
             disease and those with only non-measurable ("non-target") structural disease
             (according to modified Response Evaluation Criteria in Solid Tumors [RECIST] version
             [v] 1.1 criteria) are eligible;

        NOTE 1: Modification of the RECIST v1.1 measurable disease criteria includes a change in
        the definition of what is considered a measurable malignant lymph node; a malignant lymph
        node is considered measurable if any of the following apply:

          -  It is noted to be RAI-avid on radioactive iodine imaging (diagnostic or post-therapy
             whole body scans acceptable) and it measures >= 1 cm in the long axis,

          -  It is pathologically proven to be involved with thyroid cancer (by cytology or
             pathology) and it measures >= 1 cm in the long axis, or

          -  Its short axis is >= 1.5 cm when assessed by computed tomography (CT) scan NOTE 2:
             Patients only with biochemical evidence of disease without structural evidence of
             cancer are not eligible for this study

               -  For patients with non-measurable, structural disease the following must apply:

          -  Undetectable thyroglobulin antibody AND

          -  A serum thyroglobulin of 10 ng/ml or greater in the context of suppressed
             thyroid-stimulating hormone (TSH) (TSH =< 0.4 mcU/ml) =< 28 days prior to study
             registration; use of any thyroglobulin assay is allowed, though all serum
             thyroglobulin measurements for study purposes must be conducted with the same
             thyroglobulin assay

               -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

               -  Able to swallow and retain orally-administered medication with no clinically
                  significant gastrointestinal abnormalities that may alter absorption

               -  Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 28 days prior to

               -  Platelet count >= 100,000/mm^3 (obtained =< 28 days prior to randomization)

               -  Hemoglobin > 9.0 g/dL (obtained =< 28 days prior to randomization)

               -  Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 28 days prior
                  to randomization)

               -  Aspartate transaminase (AST) =< 2.5 x ULN (or =< 5 x ULN in presence of liver
                  metastases) (obtained =< 28 days prior to randomization)

               -  Creatinine =< 1.5 mg/dL OR calculated creatinine clearance of >= 50 ml/min by
                  either the Cockcroft-Gault formula or 24-hours urine collection analysis
                  (obtained =< 28 days prior to randomization)

               -  Negative pregnancy test performed =< 7 days prior to registration for women of
                  childbearing potential only

               -  Provide informed written consent

               -  Willing to return to enrolling institution for follow-up (during the Active
                  Monitoring Phase of the study)

          -  Note: during the Active Monitoring Phase of a study (i.e., active treatment and
             observation), participants must be willing to return to the consenting institution for

               -  Willing to provide mandatory archival tumor tissue (block or minimum of 30
                  unstained slides from a primary or recurrent/metastatic thyroid cancer) for
                  correlative research purposes; NOTE: patients with less archival tumor tissue
                  available may still be eligible for the study after discussion with Academic and
                  Community Cancer Research United (ACCRU); receipt of archival tumor tissue is not
                  required for study registration and initiation of therapy

               -  Willing to provide mandatory blood samples for correlative research purposes

        Exclusion Criteria:

          -  131I therapy =< 6 months prior to registration; Note: 131I administered solely for
             diagnostic purposes is not considered 131I therapy

          -  External beam radiation therapy =< 28 days prior to registration; note: previous
             treatment with radiation is allowed if the investigator judges it will not compromise
             patient safety on the study

          -  Having been treated with a total cumulative (lifetime) 131I therapeutic activity > 800
             mCi (excluding 131I activity administered for diagnostic scans)

          -  Treatment with chemotherapy or targeted therapy (e.g. tyrosine kinase inhibitor) =< 28
             days prior to registration

          -  Prior exposure to mitogen-activated protein kinase kinase (MEK), RAS, or RAF
             inhibitors (note: previous exposure to sorafenib is allowed) OR history of
             hypersensitivity to selumetinib, thyrotropin alpha (Thyrogen), or any excipient agents

          -  Unresolved toxicity > Common Terminology Criteria for Adverse Events (CTCAE) grade 2
             from previous anti-cancer therapy, except for alopecia

          -  Cardiac conditions as follows:

               -  Uncontrolled hypertension (blood pressure [BP] >=150/95 mmHg despite medical

               -  Left ventricular ejection fraction < 55% measured by echocardiography

               -  Atrial fibrillation with a ventricular rate > 100 beats per minute (bpm) on
                  electrocardiogram (ECG) at rest

               -  Symptomatic heart failure (New York Heart Association [NYHA] grade II-IV)

               -  Prior or current cardiomyopathy

               -  Severe valvular heart disease

               -  Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical

               -  Acute coronary syndrome =< 6 months prior to registration

          -  Ophthalmological conditions as follows:

               -  Intra-ocular pressure > 21 mmHg, or uncontrolled glaucoma (irrespective of
                  intra-ocular pressure)

               -  Current or past history of central serous retinopathy or retinal vein occlusion

          -  Symptomatic or untreated leptomeningeal disease, brain metastasis, or spinal cord

          -  Unable to follow a low iodine diet or requiring medication with high content in iodide
             (e.g., amiodarone)

          -  Received iodinated intravenous contrast within =< 2 months of registration; avoidance
             of iodinated oral contrast is also preferred but not strictly required for study
             enrollment; NOTE: those who have had iodinated intravenous contrast within this time
             frame may still be eligible if a urinary iodine analysis reveals that excess iodine
             has been cleared (defined as urinary iodine documented to be < 300 mcg/day by either a
             spot urinary iodine or 24-hour urinary iodine measurement)

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

               -  Men or women of childbearing potential who are unwilling to employ adequate

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          -  Immunocompromised patients and patients known to be human immunodeficiency virus (HIV)
             positive and currently receiving antiretroviral therapy; NOTE: patients known to be
             HIV positive, but without clinical evidence of an immunocompromised state, are
             eligible for this trial

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, hepatitis B infection, hepatitis C infection, symptomatic congestive heart
             failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
             situations that would limit compliance with study requirements

          -  Receiving any other investigational agent which would be considered as a treatment for
             the primary neoplasm. (NOTE: Performance of investigational 124I PET/CT scans is
             allowed prior to and during conduct of this study)

          -  Other active malignancy =< 2 years prior to registration that will interfere with
             conduct of this trial; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of
             the cervix; NOTE: if there is a history of prior malignancy, patients must not be
             receiving other specific treatment (chemotherapy, hormonal therapy, radiation) for
             their cancer

          -  Not willing to discontinue use of supplemental vitamin E




18 Years - N/A

Accepts Healthy Volunteers



Alan L Ho, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Academic and Community Cancer Research United


 National Cancer Institute (NCI)

Study Sponsor

Alan L Ho, Principal Investigator, Academic and Community Cancer Research United

Verification Date

July 2021